BFNH.US BioForce Nanosciences Holdings Inc
- Market cap
- USD 234M
- P/E
- -
- P/B
- 97.01x
- ROE
- -14.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BFNH.US undervalued?
Graham numberThe Graham number of BioForce Nanosciences Holdings Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioForce Nanosciences Holdings Inc fundamental analysis
No fundamental analysis for BioForce Nanosciences Holdings Inc yet.
BioForce Nanosciences Holdings Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioForce Nanosciences Holdings Inc
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. It offers private label products with distributors and manufacturing providers. The company also sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels…
Full company profileBioForce Nanosciences Holdings Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioForce Nanosciences Holdings Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 8.25K | 4.50K | 16.3K | 17.8K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.25K | 1.26K | 4.67K | 4.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.50K | -31.3K | -66.7K | -46.5K | -158M | -502K | -486K | -472K | -490K | -490K | -962K |
| EBITDA | -2.50K | -31.3K | -66.7K | -46.5K | -158M | -502K | -486K | -472K | -490K | -490K | -962K |
| Net Income | -2.50K | -31.3K | -67.7K | -46.5K | -158M | -502K | -486K | -472K | -490K | -1.29M | -274K |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -9.72 | -0.02 | -0.02 | -0.02 | -0.02 | -0.04 | -0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 16.4K | 20.9K | 35.1K | 58.9K | 39.9K | 11.1K | 734.00 | 638.00 | 862.00 | 786.00 | 2.24M |
| Total Liabilities | 14.1K | 12.7K | 5.32K | 11.6K | 400K | 873K | 1.35M | 1.82M | 2.30M | 619K | 277K |
| Shareholders' Equity | -20.9K | 8.20K | 29.8K | 47.3K | -360K | -862K | -1.35M | -1.82M | -2.30M | -619K | 1.96M |
| Cash & Short-term Investments | 14.3K | 14.3K | 29.4K | 52.9K | 39.9K | 11.1K | 734.00 | 638.00 | 862.00 | 786.00 | 31.7K |
| Total Debt | - | - | - | - | 67.2K | 116K | 174K | 221K | 274K | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 1.75K | -25.9K | -62.5K | -24.4K | -80.2K | -77.8K | -68.4K | -46.7K | -61.3K | -65.2K | -153K |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 1.75K | -25.9K | -62.5K | -24.4K | -80.2K | -77.8K | -68.4K | -46.7K | -61.3K | -65.2K | -108K |
| Ratios | |||||||||||
| ROE | - | -381.1% | -227.3% | -98.4% | - | - | - | - | - | - | -14.0% |
| ROA | -15.2% | -149.5% | -192.8% | -79.0% | -397,362.5% | -4,503.9% | -66,146.3% | -73,973.8% | -56,895.2% | -164,370.4% | -12.2% |
| Net Profit Margin | -30.3% | -694.7% | -415.3% | -261.8% | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioForce Nanosciences Holdings Inc dividends
BioForce Nanosciences Holdings Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:5 on Feb 28, 2020.
Who owns BioForce Nanosciences Holdings Inc
Ownership data of BioForce Nanosciences Holdings Inc is not available yet.
BioForce Nanosciences Holdings Inc company profile
- Company name
- BioForce Nanosciences Holdings Inc
- Ticker
- BFNH.US
- Exchange
- USA Stocks
- Sector
- Energy
- Industry
- Food Products
- Employees
- 3
- Fiscal year end
- December
- Address
- 2020 General Booth Blvd., Virginia Beach, VA, United States, 23454
- Phone
- 757 306 6090
- Website
- bioforceeclipse.com
About BioForce Nanosciences Holdings Inc
BioForce Nanosciences Holdings, Inc. focuses on providing natural vitamins, minerals, other nutritional supplements, powders, and beverages for individuals in various age ranges. It offers private label products with distributors and manufacturing providers. The company also sells its nutrition supplements to retailers, sporting goods retailers, supermarkets, mass merchandisers, and online at www.bioforceeclipse.com, as well as through social media and telemarketing channels. BioForce Nanosciences Holdings, Inc. is based in Virginia Beach, Virginia.
BioForce Nanosciences Holdings Inc management
1- Mr. Richard KaiserInterim CEO, CFO, Corp Secretary, Corp Governance Officer, Principal Acc Officer & Director · born 1966